Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-ischemic Cardiomyopathy Clear all

Conditions: Cardiomyopathies, Gender, Implantable Defibrillator User
Interventions: Not listed
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Fairhope, Alabama • Rancho Mirage, California + 41 more

Conditions: Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions: Behavioral nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions: ATI-5923, Coumadin (warfarin); Drug
Lead sponsor: ARYx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more

Conditions: Ischemic and Non-ischemic Cardiomyopathy
Interventions: Medtronic ICD with Opti Vol-Monitor; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Nonischemic Congestive Cardiomyopathy, Functional Mitral Regurgitation, Ischemic Cardiomyopathy
Interventions: Cardiac magnetic resonance (CMR); Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiomyopathy (Ischemic or Non-Ischemic)
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Congestive Heart Failure, Ischemic Cardiomyopathy, Mitral Valve Prolapse, Mitral Regurgitation, Aortic Valve Disease, Tricuspid Regurgitation
Interventions: Not listed
Lead sponsor: Woolsthorpe Technologies, LLC; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Non-ischemic Cardiomyopathy
Interventions: additional biopsies; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Congestive Heart Failure, Non-ischemic Cardiomyopathy
Interventions: Triheptanoin oil; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiomyopathy, Dilated
Interventions: Mysorba; Device
Lead sponsor: Asahi Kasei Medical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Cardiomyopathies, Insulin Resistance, Non-ischemic Cardiomyopathy, Cardiac Fibrosis, Diabetes
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 20 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Non-left Bundle Branch Block, Ischemic or Non-ischemic Cardiomyopathy
Interventions: QLV based implant strategy, Standard of care implant strategy; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 32
States / cities: Glendale, California • Los Angeles, California • Mission Viejo, California + 25 more

Conditions: Congestive Heart Failure
Interventions: AB-1002; Drug
Lead sponsor: AskBio Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Irvine, California + 31 more

Conditions: Myocardial Reperfusion Injury
Interventions: BQ-123, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions: AAV1/SERCA2a (MYDICAR), Placebo; Genetic
Lead sponsor: Celladon Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more

Conditions: Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions: Not listed
Lead sponsor: Seattle Institute for Cardiac Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions: MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only; Genetic
Lead sponsor: Celladon Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 4
States / cities: La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more

Conditions: Dilated Cardiomyopathy
Interventions: Ixmyelocel-T, Standard of Care; Biological · Other
Lead sponsor: Vericel Corporation; Industry
Eligibility: 18 Years to 86 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Cleveland, Ohio • Dallas, Texas + 2 more

Conditions: Ventricular Tachycardia
Interventions: Radiofrequency Ablation; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 19 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-ischemic Dilated Cardiomyopathy
Interventions: Autologous hMSCs, Allogeneic hMSCs; Biological
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 95 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions: MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2042
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stress Induced Cardiomyopathy
Interventions: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

OptiVol for Precision Medical Management of Heart Failure

Phenotypic Classification of FMR With CMR

DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)

Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

Electrogram-Guided Myocardial Advanced Phenotyping

Study of the Acute Effects of Triheptanoin in Heart Failure

Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)

Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

Cardiovascular Multimodality Imaging Study

Longitudinal Validation of CIRC Technologies

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

SCD-HeFT 10 Year Follow-up

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Development of CIRC Technologies

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG